BG Medicine (OTCMKTS:BGMD) vs. SeaStar Medical (NASDAQ:ICU) Head to Head Review

BG Medicine (OTCMKTS:BGMD) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

BG Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500.

Valuation & Earnings

This table compares BG Medicine and SeaStar Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
SeaStar Medical	$1.23 million	11.72	-$12.15 million	($4.80)	-0.75

BG Medicine has higher earnings, but lower revenue than SeaStar Medical.

Institutional and Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for BG Medicine and SeaStar Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
SeaStar Medical	1	0	1	0	2.00

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 121.91%. Given SeaStar Medical’s stronger consensus rating and higher probable upside, analysts plainly believe SeaStar Medical is more favorable than BG Medicine.

Profitability

This table compares BG Medicine and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
SeaStar Medical	-828.62%	-146.29%	-96.48%

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.